| __timestamp | BioMarin Pharmaceutical Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 461543000 | 241751000 |
| Thursday, January 1, 2015 | 634806000 | 322292000 |
| Friday, January 1, 2016 | 661905000 | 344320000 |
| Sunday, January 1, 2017 | 610753000 | 374644000 |
| Monday, January 1, 2018 | 696328000 | 414604000 |
| Tuesday, January 1, 2019 | 715007000 | 466000000 |
| Wednesday, January 1, 2020 | 628116000 | 535000000 |
| Friday, January 1, 2021 | 628793000 | 643000000 |
| Saturday, January 1, 2022 | 649606000 | 833000000 |
| Sunday, January 1, 2023 | 746773000 | 899625000 |
| Monday, January 1, 2024 | 747184000 | 901530000 |
Data in motion
In the competitive world of pharmaceuticals, innovation is key to staying ahead. BioMarin Pharmaceutical Inc. and Ionis Pharmaceuticals, Inc. have been at the forefront of this race, investing heavily in research and development (R&D) over the past decade. From 2014 to 2023, BioMarin's R&D spending increased by approximately 62%, while Ionis saw a staggering 272% rise. This significant investment reflects their commitment to pioneering new treatments and therapies.
BioMarin, known for its focus on rare genetic diseases, consistently allocated over 20% of its annual revenue to R&D. Meanwhile, Ionis, a leader in RNA-targeted therapeutics, has ramped up its R&D spending, surpassing BioMarin in recent years. By 2023, Ionis's R&D expenses were about 20% higher than BioMarin's, highlighting its aggressive push towards innovation. This trend underscores the dynamic nature of the pharmaceutical industry, where strategic R&D investments can lead to groundbreaking advancements.
AstraZeneca PLC vs Ionis Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Novartis AG vs BioMarin Pharmaceutical Inc.
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Teva Pharmaceutical Industries Limited or Ionis Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Insights: How BeiGene, Ltd. and Ionis Pharmaceuticals, Inc. Allocate Funds
R&D Spending Showdown: Insmed Incorporated vs Ionis Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. or Pharming Group N.V.: Who Invests More in Innovation?
Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs Viridian Therapeutics, Inc.
Research and Development Investment: Ionis Pharmaceuticals, Inc. vs Catalyst Pharmaceuticals, Inc.
Comparing Innovation Spending: Ionis Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
R&D Insights: How Ionis Pharmaceuticals, Inc. and Viridian Therapeutics, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Ionis Pharmaceuticals, Inc. and MiMedx Group, Inc.